The world is currently experiencing a huge challenge which has affected all the industries and markets. Few markets have experienced a high growth in their demand while others have faced a downfall. The extent of growth or drop in the market statistics of different industries by COVID 19 plays an important role in how the future of businesses will shape up in the near future. We at Value Market Research provide you with an impact analysis of COVID 19 on this market with its latest update in the purchased version of the report.
Global Epigenetics Drugs And Diagnostic Technologies Market Report By Drugs Mechanism Of Action (DNMT Inhibitors And HDAC Inhibitors), Technology Type (DNA Methylation And Chromatin Immunoprecipitation (CHIP) Technology), And By Regions - Industry Trends, Size, Share, Growth, Estimation And Forecast, 2021-2028
ID:VMR11210484
March 2022
Report Formats:
As per this study the global epigenetics drugs and diagnostic technologies market was valued USD XX MN (by revenue) in 2021 and is anticipated to reach USD XX MN by 2028 with a CAGR of XX%.
Epigenetics is a study of heritable changes in gene expression, it’s a change in phenotype without a change in genotype. Epigenetics drugs and diagnostic is used in screening of early stage cancer and other abnormal changes in skin cells, liver cells, brain cells, and others. It is caused by various factors such as aging and lifestyle changes along with environmental exposures.
Market Dynamics
The increasing geriatric population and rising oncology and non-oncology disorders are driving the market growth. Also, the high prevalence of cancer with advancement is screening techniques is further fuelling market growth. In addition, reduction in sequential cost and time is another factor pushing the market growth. Though, the funding and support of the organizations such as NIH and NCI for R&D are expected to boost the market growth in the forecast period. However, problems associated with quality may hamper market growth.
This detailed market study is centered on the data obtained from multiple sources and is analyzed using numerous tools including porter’s five forces analysis, market attractiveness analysis and value chain analysis. These tools are employed to gain insights of the potential value of the market facilitating the business strategists with the latest growth opportunities. Additionally, these tools also provide a detailed analysis of each application/product segment in the global market of epigenetics drugs and diagnostic technologies.
Market Segmentation
The broad epigenetics drugs and diagnostic technologies market has been sub-grouped into drugs mechanism of action and technology type. The report studies these subsets with respect to the geographical segmentation. The strategists can gain a detailed insight and devise appropriate strategies to target specific market. This detail will lead to a focused approach leading to identification of better opportunities.
By Drugs Mechanism Of Action
By Technology Types
Regional Analysis
Furthermore, the report comprises of the geographical segmentation which mainly focuses on current and forecast demand for epigenetics drugs and diagnostic technologies in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The report further focuses on demand for individual application segments in all the regions.
Global Epigenetics Drugs And Diagnostic Technologies Market Share by Region (Representative Graph)
The report also covers a detailed competitive landscape including company profiles of key players operating in the global market. The key players in the epigenetics drugs and diagnostic technologies market include 4SC AG, Acetylon Pharmaceuticals, Inc., Astex Pharmaceuticals Inc., Celenge, CellCentric Ltd., Celleron Therapeutics Ltd., Chroma Therapeutics Ltd., Eisai Pharmaceuticals, EnVivo Pharmaceuticals Inc., Epigentek Group Inc., Epizyme, Inc. Illumina Inc., MDxHealth, Merck, Merck & Company Inc., Novartis International AG, Oncolys BioPharma Inc., Pharmacyclics, Promega Corporation, Spectrum Pharmaceuticals, Syndax Pharmaceuticals, Inc., Topotarget A/S, and Valirx Plc. An in-depth view of the competitive outlook includes future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other developments with information in terms of H.Q.
METHODOLOGY:
A combination of primary and secondary research has been used to determine the market estimates and forecasts. Sources used for secondary research include (but not limited to) Paid Data Sources, Company Websites, Technical Journals, Annual Reports, SEC Filings and various other industry publications. Specific details on methodology used for this report can be provided on demand.
Epigenetics is a study of heritable changes in gene expression, it’s a change in phenotype without a change in genotype. Epigenetics drugs and diagnostic is used in screening of early stage cancer and other abnormal changes in skin cells, liver cells, brain cells, and others. It is caused by various factors such as aging and lifestyle changes along with environmental exposures.
Market Dynamics
The increasing geriatric population and rising oncology and non-oncology disorders are driving the market growth. Also, the high prevalence of cancer with advancement is screening techniques is further fuelling market growth. In addition, reduction in sequential cost and time is another factor pushing the market growth. Though, the funding and support of the organizations such as NIH and NCI for R&D are expected to boost the market growth in the forecast period. However, problems associated with quality may hamper market growth.
This detailed market study is centered on the data obtained from multiple sources and is analyzed using numerous tools including porter’s five forces analysis, market attractiveness analysis and value chain analysis. These tools are employed to gain insights of the potential value of the market facilitating the business strategists with the latest growth opportunities. Additionally, these tools also provide a detailed analysis of each application/product segment in the global market of epigenetics drugs and diagnostic technologies.
Market Segmentation
The broad epigenetics drugs and diagnostic technologies market has been sub-grouped into drugs mechanism of action and technology type. The report studies these subsets with respect to the geographical segmentation. The strategists can gain a detailed insight and devise appropriate strategies to target specific market. This detail will lead to a focused approach leading to identification of better opportunities.
By Drugs Mechanism Of Action
- DNMT Inhibitors
- Azacitidine (Vidaza)
- Decitabine (Dacogen)
- HDAC Inhibitors
- Vorinostat (Zolinza)
- Romidepsin (Istodax)
By Technology Types
- DNA Methylation
- Chromatin Immunoprecipitation (ChIP) Technology
Regional Analysis
Furthermore, the report comprises of the geographical segmentation which mainly focuses on current and forecast demand for epigenetics drugs and diagnostic technologies in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The report further focuses on demand for individual application segments in all the regions.
Global Epigenetics Drugs And Diagnostic Technologies Market Share by Region (Representative Graph)
The report also covers a detailed competitive landscape including company profiles of key players operating in the global market. The key players in the epigenetics drugs and diagnostic technologies market include 4SC AG, Acetylon Pharmaceuticals, Inc., Astex Pharmaceuticals Inc., Celenge, CellCentric Ltd., Celleron Therapeutics Ltd., Chroma Therapeutics Ltd., Eisai Pharmaceuticals, EnVivo Pharmaceuticals Inc., Epigentek Group Inc., Epizyme, Inc. Illumina Inc., MDxHealth, Merck, Merck & Company Inc., Novartis International AG, Oncolys BioPharma Inc., Pharmacyclics, Promega Corporation, Spectrum Pharmaceuticals, Syndax Pharmaceuticals, Inc., Topotarget A/S, and Valirx Plc. An in-depth view of the competitive outlook includes future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other developments with information in terms of H.Q.
METHODOLOGY:
A combination of primary and secondary research has been used to determine the market estimates and forecasts. Sources used for secondary research include (but not limited to) Paid Data Sources, Company Websites, Technical Journals, Annual Reports, SEC Filings and various other industry publications. Specific details on methodology used for this report can be provided on demand.
1 . PREFACE
1.1. Report Description
1.1.1. Objective
1.1.2. Target Audience
1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Market Research Process
1.3.2. Market Research Methodology
2 . EXECUTIVE SUMMARY
2.1. Highlights of Market
2.2. Global Market Snapshot
3 . EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES – INDUSTRY ANALYSIS
3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter’s Five Force Analysis
3.7. Market Attractiveness Analysis
3.7.1 Market Attractiveness Analysis By Drugs Mechanism Of Action
3.7.2 Market Attractiveness Analysis By Technology Types
3.7.3 Market Attractiveness Analysis By Region
4 . VALUE CHAIN ANALYSIS
4.1. Value Chain Analysis
4.2. Raw Material Analysis
4.2.1. List of Raw Materials
4.2.2. Raw Material Manufactures List
4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
4.4.1. Direct Marketing
4.4.2. Indirect Marketing
4.4.3. Marketing Channel Development Trend
5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK
5.1. Impact Analysis of Covid-19 Outbreak
5.1.1. Direct Impact on Production
5.1.2. Supply Chain and Market Disruption
5.1.3. Financial Impact on Firms and Financial Markets
5.2. COVID-19 Impact Analysis by Production, Import, Export and Demand
5.3. Market: Pre V/S Post COVID-19
5.4. Estimated Impact of the Coronavirus (COVID-19) Epidemic
5.5. COVID-19: Micro and Macro Factor Analysis
6 . GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET ANALYSIS BY DRUGS MECHANISM OF ACTION
6.1 Overview by Drugs Mechanism Of Action
6.2 Historical and Forecast Data
6.3 Analysis by Drugs Mechanism Of Action
6.4 DNMT Inhibitors Historic and Forecast Sales by Regions
6.5 HDAC Inhibitors Historic and Forecast Sales by Regions
7 . GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET ANALYSIS BY TECHNOLOGY TYPES
7.1 Overview by Technology Types
7.2 Historical and Forecast Data
7.3 Analysis by Technology Types
7.4 DNA Methylation Historic and Forecast Sales by Regions
7.5 Chromatin Immunoprecipitation (ChIP) Technology Historic and Forecast Sales by Regions
8 . GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET ANALYSIS BY GEOGRAPHY
8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
8.3.1. Overview, Historic and Forecast Sales Analysis
8.3.2. North America By Segment Sales Analysis
8.3.3. North America By Country Sales Analysis
8.3.4. United State Sales Analysis
8.3.5. Canada Sales Analysis
8.3.6. Mexico Sales Analysis
8.4. Europe Sales Analysis
8.4.1. Overview, Historic and Forecast Sales Analysis
8.4.2. Europe by Segment Sales Analysis
8.4.3. Europe by Country Sales Analysis
8.4.4. United Kingdom Sales Analysis
8.4.5. France Sales Analysis
8.4.6. Germany Sales Analysis
8.4.7. Italy Sales Analysis
8.4.8. Russia Sales Analysis
8.4.9. Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
8.5.1. Overview, Historic and Forecast Sales Analysis
8.5.2. Asia Pacific by Segment Sales Analysis
8.5.3. Asia Pacific by Country Sales Analysis
8.5.4. China Sales Analysis
8.5.5. India Sales Analysis
8.5.6. Japan Sales Analysis
8.5.7. South Korea Sales Analysis
8.5.8. Australia Sales Analysis
8.5.9. Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
8.6.1. Overview, Historic and Forecast Sales Analysis
8.6.2. Latin America by Segment Sales Analysis
8.6.3. Latin America by Country Sales Analysis
8.6.4. Brazil Sales Analysis
8.6.5. Argentina Sales Analysis
8.6.6. Peru Sales Analysis
8.6.7. Chile Sales Analysis
8.6.8. Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
8.7.1. Overview, Historic and Forecast Sales Analysis
8.7.2. Middle East & Africa by Segment Sales Analysis
8.7.3. Middle East & Africa by Country Sales Analysis
8.7.4. Saudi Arabia Sales Analysis
8.7.5. UAE Sales Analysis
8.7.6. Israel Sales Analysis
8.7.7. South Africa Sales Analysis
8.7.8. Rest Of Middle East And Africa Sales Analysis
9 . COMPETITIVE LANDSCAPE OF THE EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES COMPANIES
9.1. Epigenetics Drugs And Diagnostic Technologies Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments
10 . COMPANY PROFILES OF EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES INDUSTRY
10.1. Top 10 Company Share Analysis
10.2. Market Concentration Rate
10.3. 4SC AG
10.3.1. Company Overview
10.3.2. Company Revenue
10.3.3. Products
10.3.4. Recent Developments
10.4. Acetylon Pharmaceuticals Inc.
10.4.1. Company Overview
10.4.2. Company Revenue
10.4.3. Products
10.4.4. Recent Developments
10.5. Astex Pharmaceuticals Inc.
10.5.1. Company Overview
10.5.2. Company Revenue
10.5.3. Products
10.5.4. Recent Developments
10.6. Celenge
10.6.1. Company Overview
10.6.2. Company Revenue
10.6.3. Products
10.6.4. Recent Developments
10.7. CellCentric Ltd.
10.7.1. Company Overview
10.7.2. Company Revenue
10.7.3. Products
10.7.4. Recent Developments
10.8. Celleron Therapeutics Ltd.
10.8.1. Company Overview
10.8.2. Company Revenue
10.8.3. Products
10.8.4. Recent Developments
10.9. Chroma Therapeutics Ltd.
10.9.1. Company Overview
10.9.2. Company Revenue
10.9.3. Products
10.9.4. Recent Developments
10.10. Eisai Pharmaceuticals
10.10.1. Company Overview
10.10.2. Company Revenue
10.10.3. Products
10.10.4. Recent Developments
10.11. EnVivo Pharmaceuticals Inc.
10.11.1. Company Overview
10.11.2. Company Revenue
10.11.3. Products
10.11.4. Recent Developments
10.12. Epigentek Group Inc.
10.12.1. Company Overview
10.12.2. Company Revenue
10.12.3. Products
10.12.4. Recent Developments
10.13. Epizyme Inc.
10.13.1. Company Overview
10.13.2. Company Revenue
10.13.3. Products
10.13.4. Recent Developments
10.14. Illumina Inc.
10.14.1. Company Overview
10.14.2. Company Revenue
10.14.3. Products
10.14.4. Recent Developments
10.15. MDxHealth
10.15.1. Company Overview
10.15.2. Company Revenue
10.15.3. Products
10.15.4. Recent Developments
10.16. Merck
10.16.1. Company Overview
10.16.2. Company Revenue
10.16.3. Products
10.16.4. Recent Developments
10.17. Merck & Company Inc.
10.17.1. Company Overview
10.17.2. Company Revenue
10.17.3. Products
10.17.4. Recent Developments
10.18. Novartis International AG
10.18.1. Company Overview
10.18.2. Company Revenue
10.18.3. Products
10.18.4. Recent Developments
10.19. Oncolys BioPharma Inc.
10.19.1. Company Overview
10.19.2. Company Revenue
10.19.3. Products
10.19.4. Recent Developments
10.20. Pharmacyclics
10.20.1. Company Overview
10.20.2. Company Revenue
10.20.3. Products
10.20.4. Recent Developments
10.21. Promega Corporation
10.21.1. Company Overview
10.21.2. Company Revenue
10.21.3. Products
10.21.4. Recent Developments
10.22. Spectrum Pharmaceuticals
10.22.1. Company Overview
10.22.2. Company Revenue
10.22.3. Products
10.22.4. Recent Developments
10.23. Syndax Pharmaceuticals Inc.
10.23.1. Company Overview
10.23.2. Company Revenue
10.23.3. Products
10.23.4. Recent Developments
10.24. Topotarget A/S
10.24.1. Company Overview
10.24.2. Company Revenue
10.24.3. Products
10.24.4. Recent Developments
10.25. Valirx Plc.
10.25.1. Company Overview
10.25.2. Company Revenue
10.25.3. Products
10.25.4. Recent Developments
*Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies
LIST OF TABLES
- Market Snapshot
- Drivers : Impact Analysis
- Restraints : Impact Analysis
- List of Raw Material
- List of Raw Material Manufactures
- List of Potential Buyers
- COVID-19 Impact Analysis by Production, Import, Export and Demand
- Pre V/S Post COVID-19
- Estimated Impact Of The Coronavirus (Covid-19) Epidemic
- COVID-19: Micro and Macro Factor Analysis
- Analysis by Drugs Mechanism Of Action (USD MN)
- DNMT Inhibitors Market Sales by Geography (USD MN)
- HDAC Inhibitors Market Sales by Geography (USD MN)
- Analysis Market by Technology Types (USD MN)
- DNA Methylation Market Sales by Geography (USD MN)
- Chromatin Immunoprecipitation (ChIP) Technology Market Sales by Geography (USD MN)
- Global Epigenetics Drugs And Diagnostic Technologies Market Sales by Geography (USD MN)
- North America Market Analysis (USD MN)
- United State Market Analysis (USD MN)
- Canada Market Analysis (USD MN)
- Mexico Market Analysis (USD MN)
- Europe Market Analysis (USD MN)
- Europe Market Estimate by Country (USD MN)
- United Kingdom Market Analysis (USD MN)
- France Market Analysis (USD MN)
- Germany Market Analysis (USD MN)
- Italy Market Analysis (USD MN)
- Russia Market Analysis (USD MN)
- Spain Market Analysis (USD MN)
- Rest of Europe Market Analysis (USD MN)
- Asia Pacific Market Analysis (USD MN)
- China Market Analysis (USD MN)
- Japan Market Analysis (USD MN)
- India Market Analysis (USD MN)
- South Korea Market Analysis (USD MN)
- Australia Market Analysis (USD MN)
- Rest of Asia Pacific Market Analysis (USD MN)
- Latin America Market Analysis (USD MN)
- Brazil Market Analysis (USD MN)
- Argentina Market Analysis (USD MN)
- Peru Market Analysis (USD MN)
- Chile Market Analysis (USD MN)
- Rest of Latin America Market Analysis (USD MN)
- Middle East & Africa Market Analysis (USD MN)
- Saudi Arabia Market Analysis (USD MN)
- UAE Market Analysis (USD MN)
- Israel Market Analysis (USD MN)
- South Africa Market Analysis (USD MN)
- Rest of Middle East and Africa Market Analysis (USD MN)
- Partnership/Collaboration/Agreement
- Mergers And Acquisiton
LIST OF FIGURES
- Research Scope of Epigenetics Drugs And Diagnostic Technologies Report
- Market Research Process
- Market Research Methodology
- Global Epigenetics Drugs And Diagnostic Technologies Market Size, by Region (USD MN)
- Porters Five Forces Analysis
- Market Attractiveness Analysis by Drugs Mechanism Of Action
- Market Attractiveness Analysis by Technology Types
- Market Attractiveness Analysis by Region
- Value Chain Analysis
- Global Market Analysis by Drugs Mechanism Of Action (USD MN)
- DNMT Inhibitors Market Sales by Geography (USD MN)
- HDAC Inhibitors Market Sales by Geography (USD MN)
- Global Market Analysis by Technology Types (USD MN)
- DNA Methylation Market Sales by Geography (USD MN)
- Chromatin Immunoprecipitation (ChIP) Technology Market Sales by Geography (USD MN)
- Global Market by Revenue
- North America Market by Revenue
- Europe Market by Revenue
- Asia Pacific Market by Revenue
- Latin America Market by Revenue
- Middle East & Africa Market by Revenue
- Recent Development in Industry
- Top 10 Company Share Analysis
* Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.
Related Categories
Healthcare
Buy Chapters or Sections
Avail customized purchase options to meet your exact research needs:
- Buy sections of this report
- Buy country level reports
- Request for historical data
- Request discounts available for Start-Ups & Universities
Objectives of Study
- Define and measure the global market
- Volume or revenue forecast of the global market and its various sub-segments with respect to main geographies
- Analyze and identify major market trends along with the factors driving or inhibiting the market growth
- Study the company profiles of the major market players with their market share
- Analyze competitive developments